» Articles » PMID: 7002569

Impairment of Insulin Secretion in Man by Nifedipine

Overview
Specialty Pharmacology
Date 1980 Nov 1
PMID 7002569
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of nifedipine, a calcium antagonist, on carbohydrate metabolism and insulin secretion was evaluated in patients who required treatment with this drug. 20 subjects underwent two oral glucose tolerance tests (100 g), one under basal conditions, and the other after ten days of treatment with nifedipine 30 mg/day by mouth, in three divided doses. 10 subjects had normal glucose tolerance; in them nifedipine administration reduced the insulin response to oral glucose in the first 60 min, but improved glucose tolerance. The other 10 subjects had impaired glucose tolerance and nifedipine treatment resulted in a further reduction both of insulin secretion and glucose tolerance. No such effects were seen in the placebo (weight- and disease-matched) group. The mechanism by which nifedipine influences carbohydrate metabolism and insulin secretion is discussed.

Citing Articles

Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Baba T, Ishizaki T Drugs. 2017; 43(4):464-489.

PMID: 28421556 DOI: 10.2165/00003495-199243040-00004.


Insulin granule biogenesis, trafficking and exocytosis.

Hou J, Min L, Pessin J Vitam Horm. 2009; 80:473-506.

PMID: 19251047 PMC: 4324607. DOI: 10.1016/S0083-6729(08)00616-X.


Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems.

Ernsberger P, Koletsky R Naunyn Schmiedebergs Arch Pharmacol. 2006; 373(4):245-58.

PMID: 16783586 DOI: 10.1007/s00210-006-0080-3.


Glucose-sensing mechanisms in pancreatic beta-cells.

MacDonald P, Joseph J, Rorsman P Philos Trans R Soc Lond B Biol Sci. 2005; 360(1464):2211-25.

PMID: 16321791 PMC: 1569593. DOI: 10.1098/rstb.2005.1762.


Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension.

Maccario M, Oleandri S, Avogadri E, Rossetto R, Grottoli S, Procopio M J Endocrinol Invest. 1998; 21(1):56-63.

PMID: 9633024 DOI: 10.1007/BF03347287.


References
1.
Somers G, Devis G, Van Obberghen E, Malaisse W . Calcium-antagonists and islet function. VI. Effects of barium. Pflugers Arch. 1976; 365(1):21-8. DOI: 10.1007/BF00583624. View

2.
NAYLER W, Szeto J . Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res. 1972; 6(2):120-8. DOI: 10.1093/cvr/6.2.120. View

3.
Giugliano D, Torella R, Sgambato S, DOnofrio F . Effects of alpha-and beta-adrenergic inhibition and somatostatin on plasma glucose, free fatty acids, insulin glucagon and growth hormone responses to prostaglandin E1 in man. J Clin Endocrinol Metab. 1979; 48(2):302-8. DOI: 10.1210/jcem-48-2-302. View

4.
Marchand J, Malaisse W . The role of calcium in glucagon release. Studies with verapamil. Diabetes. 1978; 27(10):996-1004. DOI: 10.2337/diab.27.10.996. View

5.
FLECKENSTEIN A, Tritthart H, DORING H, Byon K . [BAY a 1040--a highly potent Ca ++ -antagonistic inhibitor of electro-mechanical coupling processes in mammalian myocardium]. Arzneimittelforschung. 1972; 22(1):22-33. View